Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Mizuho Discusses Biogen (BIIB) Seizure Patient
December 9, 2016 2:15 PM ESTMizuho analyst Salim Syed discussed Biogen (NASDAQ: BIIB) Aducanumab's LTE seizure patient, which has the stock well off highs (+0.4%).
"On the seizure patient, we spoke to the company (they weren't willing to say much beyond the slide) ... this is a new... More
Biogen (BIIB) Shares Should Trade Higher on CTAD Data - BMO Capital
December 9, 2016 6:29 AM ESTBMO Capital analyst M. Ian Somaiya expects shares of Biogen (NASDAQ: BIIB) to trade higher CTAD data, which show: 1) solanezumab caused small yet consistent improvements on secondary endpoints, including CDR-SB (aducanumab's P3 endpoint); and (2) aducanumab titration yielded efficacy similar to 6-10mg/kg... More
UPDATE: Biogen (BIIB), Biotechs Gain Mid-Day
December 8, 2016 3:03 PM EST(Updated - December 8, 2016 3:07 PM EST)
Biogen (NASDAQ: BIIB), other biotechs gain mid-day. May be related to conference commentary.
UPDATE: The upside is said related to aducanumab data, which was released from embargo earlier. Adam Feuerstein tweeted:
... More
